Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer

- Percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer is firstly showed.
- A potentially effective approach for the control of tumour growth in advanced RCC patients is proposed.
- Percutaneous cryoablation combined with allogenic NK cell immunotherapy have a synergistic effect.

In this study, the clinical efficacy of cryosurgery combined with allogenic NK cell immunotherapy for advanced renal cell cancer was evaluated. From July to December 2016, we enrolled 60 patients who met the enrollment criteria and divided them into two groups: (1) the simple cryoablation group (n = 30); and (2) the cryoablation combined with allogenic NK cells group (n = 30). The clinical efficacy, quality of life, immune function, and other related indicators were evaluated. Combining allogeneic NK cells with cryoablation had a synergistic effect, not only enhancing the immune function and improving the quality of life of the patients, but also significantly exhibiting good clinical efficacy of the patients. This study is the first clinical trial that has evaluated the safety and efficacy of allogenic NK cells combined with cryosurgery for the treatment of renal cell cancer.